Overview

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Status:
Terminated

Trial end date:
2016-04-13

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, prospective pilot study of CDX-301 with or without plerixafor as a stem cell mobilizer for allogeneic transplantation (stem cells that come from another person). HLA-matched sibling healthy volunteers (donors) and patients with protocol specified hematologic malignancies (recipients) will be enrolled.

Phase:

Phase 2

Details

Lead Sponsor:

Celldex Therapeutics

Treatments:

JM 3100
Plerixafor